Monitoring mycophenolate mofetil in lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial checks how well the drug mycophenolate mofetil works in people with lupus kidney disease by measuring drug levels in the blood. It aims to help doctors adjust doses for better control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have lupus with active kidney inflammation (class III-V) confirmed by a kidney biopsy in the last 6 months or have high protein in your urine
- You are taking mycophenolate mofetil (MMF) as part of your maintenance treatment within the first 3 months
- You live in one of these cities in Brazil: São Luís, São José de Ribamar, or Paço do Lumiar
- You are not pregnant, breastfeeding, or allergic to MMF
- You do not have a severe active infection, unstable kidney dialysis, or severe liver failure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.